NanoViricides (NYSEMKT:NNVC) jumps 36% after hours in reaction to its announcement related to its development plans for a drug to treat COVID-19 infection.
Management intends to conduct initial testing of its drug candidates in its own virology laboratory using low-threat coronavirus strains that have been normally circulating in the human population. If successful, it has the ability to make "kilogram quantities" in just a few weeks which, it says, would be sufficient to treat several hundred to a few thousand patients.
Source seeking alpha
Management intends to conduct initial testing of its drug candidates in its own virology laboratory using low-threat coronavirus strains that have been normally circulating in the human population. If successful, it has the ability to make "kilogram quantities" in just a few weeks which, it says, would be sufficient to treat several hundred to a few thousand patients.
Source seeking alpha